"Amifostine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
| Descriptor ID |
D004999
|
| MeSH Number(s) |
D02.705.400.625.050 D02.705.539.345.050 D02.886.300.692.050
|
| Concept/Terms |
Amifostine- Amifostine
- Amifostine Trihydrate
- Trihydrate, Amifostine
- APAETP
|
Below are MeSH descriptors whose meaning is more general than "Amifostine".
Below are MeSH descriptors whose meaning is more specific than "Amifostine".
This graph shows the total number of publications written about "Amifostine" by people in this website by year, and whether "Amifostine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amifostine" by people in Profiles.
-
Radioprotection With Amifostine Enhances Bone Strength and Regeneration and Bony Union in a Rat Model of Mandibular Distraction Osteogenesis. Ann Plast Surg. 2018 Feb; 80(2):176-180.
-
Amifostine Treatment Mitigates the Damaging Effects of Radiation on Distraction Osteogenesis in the Murine Mandible. Ann Plast Surg. 2016 Aug; 77(2):164-8.
-
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014 Jun; 16(6):848-55.
-
Quantitative histologic evidence of amifostine-induced cytoprotection in an irradiated murine model of mandibular distraction osteogenesis. Plast Reconstr Surg. 2012 Dec; 130(6):1199-1207.
-
Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer. Am J Ther. 2011 May; 18(3):206-15.
-
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
-
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. Clin Cancer Res. 2010 Feb 01; 16(3):1049-57.
-
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
-
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
-
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.